Author:
Jiang Jingting,Zhang Xiaoying,Wu Changping,Qin Xihu,Luo Guanghua,Deng Haifeng,Lu Minyang,Xu Bin,Li Min,Ji Mei,Xu Ning
Abstract
Abstract
Objective
To determine plasma apolipoprotein M (apoM) levels and other lipid profiles in hepatocellular carcinoma (HCC) patients compared to other chronic liver diseases and normal subjects.
Materials and methods
36 HCC, 68 chronic hepatitis, 29 liver cirrhosis patients and 64 normal controls were subjected in the present study. Serum lipids, lipoproteins, apolipoprotein AI (apoAI) and apoB were determined by the conventional methods. Plasma apoM levels were semi-quantitatively determined by both dot-blotting and western blotting analysis.
Results
Serum levels of triglycerides (TG), HDL-cholesterol, apoAI and lipoprotein (a) (Lp(a)) were significantly lower in the HCC patients than in the normal subjects, whereas there were no obvious differences on serum total cholesterol, LDL-cholesterol and apoB between HCC patients and normal subjects. However, plasma apoM levels in HCC patients were significantly increased than those in the normal subjects, but lower than those in the chronic hepatitis and cirrhosis patients.
Conclusion
It is concluded that serum TG, apoAI, HDL-C and Lp(a) were significantly decreased in HCC patients than in controls, whereas plasma apoM levels were significantly increased in the HCC patients. Decreased serum TG, apoAI, HDL-C and Lp(a) may reflect the liver damage in HCC patients, whereas the clinical significance of increased plasma apoM levels in relation to HCC is not clear.
Publisher
Springer Science and Business Media LLC
Subject
Biochemistry, medical,Clinical Biochemistry,Endocrinology,Endocrinology, Diabetes and Metabolism
Reference33 articles.
1. Nissen NN, Martin P: Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol. 2002, 35 (5 Suppl 2): S79-85. 10.1097/00004836-200211002-00003
2. Zhang SW, Li LD, Lu FZ, Mu R, Sun XD, HuangP XM, Sun J, Zhou YC, XD D: Mortality of primary liver cancer in China from 1990 through 1992(Chinese article). Chinese Journal of Oncology. 1999, 21 (4): 245-249
3. Harrison TJ, Chen JY, Zuckerman AJ: Hepatitis B and primary liver cancer. Cancer Treat Rev. 1986, 13 (1): 1-16. 10.1016/0305-7372(86)90011-3
4. Buendia MA: Mammalian hepatitis B viruses and primary liver cancer. Semin Cancer Biol. 1992, 3 (5): 309-320.
5. Rabe C, Cheng B, Caselmann WH: Molecular mechanisms of hepatitis B virus-associated liver cancer. Dig Dis. 2001, 19 (4): 279-287. 10.1159/000050694
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献